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OBJECTIVE—A restricted region of proinsulin located in the B
chain and adjacent region of C-peptide has been shown to
contain numerous candidate epitopes recognized by CD8

T-cells. Our objective is to characterize HLA class I–restricted
epitopes located within the preproinsulin leader sequence.
RESEARCH DESIGN AND METHODS—Seven 8- to 11-mer
preproinsulin peptides carrying anchoring residues for HLA-A1,
-A2, -A24, and -B8 were selected from databases. HLA-A2–
restricted peptides were tested for immunogenicity in transgenic
mice expressing a chimeric HLA-A*0201/2-microglobulin mole-
cule. The peptides were studied for binding to puriﬁed HLA class
I molecules, selected for carrying COOH-terminal residues gen-
erated by proteasome digestion in vitro and tested for recogni-
tion by human lymphocytes using an ex vivo interferon- (IFN-)
ELISpot assay.
RESULTS—Five HLA-A2–restricted peptides were immuno-
genic in transgenic mice. Murine T-cell clones speciﬁc for these
peptides were cytotoxic against cells transfected with the pre-
proinsulin gene. They were recognized by peripheral blood
mononuclear cells (PBMCs) from 17 of 21 HLA-A2 type 1 diabetic
patients. PBMCs from 25 of 38 HLA-A1, -A2, -A24, or -B8 patients
produced IFN- in response to six preproinsulin peptides
covering residues 2–25 within the preproinsulin region. In
most patients, the response was against several class I–
restricted peptides. T-cells recognizing preproinsulin peptide
were characterized as CD8
 T-cells by staining with peptide/
HLA-A2 tetramers.
CONCLUSIONS—We deﬁned class I–restricted epitopes lo-
cated within the leader sequence of human preproinsulin through
in vivo (transgenic mice) and ex vivo (diabetic patients) assays,
illustrating the possible role of preproinsulin-speciﬁc CD8

T-cells in human type 1 diabetes. Diabetes 58:394–402, 2009
T
ype 1 diabetes involves the activation of lympho-
cytes against -cell autoantigens. In animals, the
predominant role of T-cells is supported by
experiments in which diabetes is transferred by
diabetogenic T-cells, is prevented by antibodies that inter-
fere with T-cell activation, or fails to develop in diabetes-
prone mice in which key genes in T-cell differentiation or
activation are deﬁcient. In humans, T-cells are predomi-
nant within insulitis at early stages of diabetes. Moreover,
type 1 diabetes has been reported in an immunodeﬁcient
patient deprived of B-cells (1).
Major histocompatibility complex (MHC) class II–
restricted CD4
 T-cells are central in the diabetes process,
but CD8
 T-cells play a pivotal role in its initiation in NOD
mice (2). In human, CD8
 T-cells are predominant, and a
high percentage of interferon- (IFN-)-positive cells is
detected within insulitis in recent-onset diabetes in most
observations (3–6). Recurrent diabetes in recipients of
isografts from a discordant twin is accompanied by pre-
dominant CD8
 T-cell inﬁltration (7).
Among -cell autoantigens, proinsulin has been ascribed a
key role in diabetes. In humans, insulin and proinsulin are
common targets of autoantibodies (8,9) and T-cells (10–17)
in diabetic and pre-diabetic individuals. Anti-insulin anti-
bodies are the ﬁrst to be detected in children at risk for
diabetes and carry a high positive predictive value for diabe-
tes (9). In NOD mice, injection of insulin-speciﬁc T-cell
clones accelerate diabetes (18). Protection from diabetes is
obtained by injecting insulin in pre-diabetic mice (19). In
addition, proinsulin 1
/ or 2
/ NOD mice show delayed or
accelerated diabetes, respectively (20,21).
Several new -cell HLA class I–restricted epitopes have
been reported recently (22–27). We and others have shown
that a restricted region of human proinsulin located in the
B chain and adjacent C-peptide clusters proteasome cleav-
age sites generating correct COOH-termini of putative
MHC class I peptides and many epitopes that are recog-
nized by diabetic CD8
 T-cells (22,23). Recognition of
epitopes that are located within the C-peptide and C-
peptide–B chain junction, including residues that are ex-
cised during the secretion process, makes a strong case for
proinsulin as an autoantigen in diabetes. Despite strong
evidence that leader sequence peptides are presented by
class I HLA molecules, especially HLA-A2.1 (28), only two
HLA A2.1 preproinsulin leader sequence peptides have
been identiﬁed (26,27).
To characterize class I–restricted epitopes within the
preproinsulin leader sequence, we selected 8- to 11-mer
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394 DIABETES, VOL. 58, FEBRUARY 2009peptides carrying anchoring residues for class I molecules.
These peptides were studied for immunogenicity in HLA-
A*0201 transgenic mice (29). Mouse CD8
 T-cell clones
speciﬁc to HLA-A*0201–restricted peptides were tested for
cytotoxicity against HLA-A2 target cells transfected with
the preproinsulin gene. In human, peptides were studied
for binding to common class I molecules, for carrying
COOH-terminal residues generated by proteasome diges-
tion, and for recognition by peripheral blood mononuclear
cells (PBMCs) from diabetic patients.
RESEARCH DESIGN AND METHODS
Mice. HHD mice express the chimeric HLA-A*0201 HHD monochain contain-
ing the HLA-A*0201 1/2 domains and the H-2D
b 3 domain linked at its NH2-
terminus to the human 2m COOH-terminus by a 15-residue linker peptide
(29).
Cytotoxicity assays. Cytotoxicity assays were performed using RMA-S cells
transfected with the HHD monochain or P815-HTR (high-efﬁciency transfec-
tion recipient, DBA/2, H-2
d) mouse mastocytoma cells expressing HLA-A2.1
and human preproinsulin as targets. P815-HTR cells were electroporated with
respectively 20 g HLA-A2.1 plasmid (blue script) and 2 g construct plasmid
preproinsulin human linearized DNA (PcDNA3.1
; Invitrogen) at 250 V using
an Easyject gene pulser. After 24 h, cells were transferred in selective medium
containing 500 g/ml G418 (Gibco-BRL, Paisley, U.K.) and cloned by limiting
dilution. Neomycine-resistant clones expressing the HLA-A2.1 monochain
were analyzed by ﬂow cytometry using anti-H2m ﬂuorescein isothiocyanate
(FITC)-conjugated antibody. Transfected cells expressing high preproinsulin
RNA levels were selected by RT-PCR using -actin RNA as internal standard.
Peptide immunizations were performed by injecting HHD mice with 100 g
peptide and 140 g I-A
b–restricted helper peptide from the hepatitis B core
protein (TPPAYRPPNAPIL) in incomplete Freund’s adjuvant subcutaneously
at the base of the tail. At day 11, spleen cells were restimulated in vitro for 6
days in the presence of irradiated (3,500 rad) HHD mouse spleen cells
preactivated for 3 days by 10 g/ml lipopolysaccharide 055:B5 (Sigma) and
then pulsed with 5 g/ml peptides. Spleen cells were recovered and tested for
cytotoxicity against HHD-transfected RMA-S cells pulsed with tested or
control peptide using chromium release assay.
CTL lines and clones were obtained by culturing cells showing cytolytic
activity in RPMI supplemented with 10% FCS and 0.1 mmol/l 2-mercaptoetha-
nol and restimulated weekly with peptide (1 g/ml down to 0.05 g/ml)-pulsed
HHD cells.
Patients. Type 1 diabetic patients had anti-GAD, -insulin, –islet antigen 2, or
–islet cell antibodies at diagnosis.
Recent-onset patients (n  26, 12 women and 14 men) were studied within
3 months of diagnosis. Long-standing patients (n  12, 4 women and 8 men)
had been insulin treated for 5–40 years at study. Control subjects included 12
healthy blood donors (4 women and 8 men) and 6 type 2 diabetic patients (2
women and 4 men), 3 of whom were insulin treated (Table 1). Informed
consent was obtained from all patients. PBMCs were isolated by Ficoll Paque
density gradient centrifugation (Pharmacia Biotech, Uppsala, Sweden) and
analyzed immediately. HLA class I and class II alleles were determined by
serological typing and genotyping, respectively, and class I alleles were
conﬁrmed by genotyping.
Peptides. Seven 8- to 11-mer preproinsulin peptides carrying putative binding
motifs for HLA-A1, -A2, -A24, and -B8 alleles were selected as predicted from
known viral peptide sequences and databases (http://www-bimass.cit.nih.gov;
http://www.syfpeithi.de). Selection was based on bimass and syfpeithi scores
40 and 14, respectively, or on known viral peptide sequences (J.C., personal
communication). Six HLA-A2–restricted peptides (one of them carrying
binding motifs for HLA-A24 and -B8) and one peptide containing binding
motifs for HLA-A1 and -A24 were selected (Table 2). Peptides were synthe-
sized and puriﬁed (23). Peptide nomenclature refers to NH2- and COOH-
terminal positions along the human preproinsulin sequence.
Peptide-binding assay. HLA heavy (H) chains prepared as reported previ-
ously (30) were incubated with 2 g/ml exogenous 2m (Sigma, Steinheim,
Germany) and with 10
4,1 0
6, and 10
8 mol/l exogenous peptides in
Eppendorf microtubes (Eppendorf-Netheler-Hinz, Hamburg, Germany) for 1 h
at room temperature and then for 24 h at 4°C. Reassembled HLA molecules
were further incubated for 90 min at 37°C in 96-well microtiter plates coated
with anti-HLA monoclonal antibodies (BB7.2 for HLA-A2, B1.23.2 for HLA-B
molecules, and PA2.6 for HLA-A and -B molecules). Correctly folded HLA
complexes were revealed with anti-2m antibodies coupled to alkaline
phosphatase and 4-methyl-umbelliferyl phosphate (M-8883; Sigma) as sub-
strate. Fluorescence generated was measured at 360/460 nm in a Microﬂuor
reader (Victor 1420; Wallac, Turku, Finland). Percentage of binding was
deﬁned as the binding of tested peptide over the binding of the reference viral
peptide  100. Reference peptides were inﬂuenza virus matrix M.58–66
(GILGFVFTL) for HLA-A2, inﬂuenza virus PB1 peptide 591–599 (VSDGG
PNLY) for HLA-A1, EBV LMP2 419–427 (TYGPFMSL) for A-24, and HIV Nef
90–97 (FLKEKGGL) for HLA-B8.
Proteasome digestion. Preproinsulin peptide 1–28, which covers leader
sequence and adjacent B chain residues (MALWMRLLPLLALLALWGPD
PAAAFVNQ) was digested by a proteasome-enriched extract obtained from
T1 lymphoblastoid cells (23). Cleavage products were separated by reversed-
phase high-performance liquid chromatography (RP-HPLC; Perkin-Elmer,
Norwalk, CT) on a C18 Nucleosil column (10 m, 250  4.0 mm; Macherey-
Nagel, Hoerdt, France). Mass analyses were performed on a MALDI-Tof
spectrometer in a reﬂectron-delayed extraction ion source over a mass range
of 500–3,200 Da and recorded with a Voyager-DE-Pro mass spectrometer
(PerSeptive Biosystems, Framingham, MA). Monoisotopic masses were cal-
culated, and peptides corresponding to computed masses were identiﬁed (23).
TABLE 1
Patients and control individuals
P -DRB1* -A, -B* P -DRB1* -A, -B* C -DRB1* -A, -B*
R1 03/04 A2–3, B18–38 R20 03/04 A1–24, B8- C1 nd A2–29, B7–44
R2 04/13 A2–24, B27- R21 03/04 A24–25, B18–56 C2 nd A2–3, B38–51
R3 03/11 A2–30, B16–18 R22 03/03 A1–24, B16–39 C3 nd A24–28, B7–8
R4 03/16 A2-, B45–18 R23 04/08 A3–24, B39–49 C4 nd A1–30, B8–13
R5 01/03 A2-, B8- R24 04/08 A24–80, B44–51 C5 nd A1–32, B8–13
R6 03/16 A2–11, B7–55 R25 03/03 A9–10, B8–14 C6 nd A2–31, B35–60
R7 03/04 A2-, B62–52 R26 03/04 A1–2, B8–15 C7 nd A2-, B8-
R8 03/04 A2-, B8–44 L1 03/04 A2-, B35–62 C8 nd A2–3, B7–12
R9 03/11 A2-, B8–51 L2 03/04 A2–29, B7–35 C9 nd A2-, B27–44
R10 04/04 A2–3, B14–44 L3 01/01 A2–24, B7–35 C10 03/04 A1–2, B8–50
R11 04/13 A2–3, B15–50 L4 04/04 A2-, B39–62 C11 nd A2–3, B7–50
R12 01/04 A2–3, B15–35 L5 03/03 A1–24, B8–45 C12 nd A1–3, B8–27
R13 03/04 A2–24, B49- L6 03/04 A1–24, B8–49 D1 nd A2–10, B12–44
R14 07/13 A1–2, B12–44 L7 04/13 A11–24, B50–62 D2 03/15 A2-, B35–44
R15 03/13 A2-, B8- L8 03/04 A1–3, B8–49 D3 03/14 A1–11, B8–55
R16 03/04 A2–3, B8–18 L9 03/03 A3–31, B8–51 D4† 03/13 A2-, B38–45
R17 04/16 A1–24, B8–44 L10 03/04 A1–9, B8–21 D5† 01/11 A1–2, B7-
R18 03/08 A3–24, B8–58 L11 03/04 A1-, B8–38 D6† 03/07 A1–19, B8–44
R19 01/04 A3–24, B35–47 L12 03/04 A1-, B8–44
P, patients; R, recent-onset diabetes; L, long-standing diabetes; C, healthy control subjects; D, type 2 diabetic control subjects; nd, not done.
*HLA alleles. †Insulin treated.
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(ELISpot) was performed as previously described (23). Background IFN-
response was evaluated in three to six wells containing 3  10
5 cells/well
incubated without peptide. Responses were considered positive when the
number of spots in the presence of peptide was above background 3 SD.
Positive controls consisted of three wells containing 3  10
4 cells/well
stimulated with 1 g/ml phytohemagglutinin and three wells containing 3 
10
5 cells/well stimulated with 10 g/ml viral peptides (peptide M.58–66 from
inﬂuenza virus matrix for HLA-A2, nucleoprotein NP44–52 for HLA-A1, and
NP380–388 for HLA-B8). Negative controls were HIV Nef 83–91 peptide for
HLA-A2 and Nef 182–189 peptide for HLA-B8. A stimulation score was
calculated to take into account interassay variability (stimulation score 
mean number of spots in response to peptide  mean number of spots in
absence of peptide).
Expansion of human proinsulin-speciﬁc T-cells. PBMCs (3  10
6 cells/ml)
were incubated in presence of 10 g/ml peptide for2ha t37°C, washed,
seeded in a six-well plate, maintained for 14 days, and fed on days 4 and 7 by
replacing one-half supernatant with fresh medium containing 10 units/ml
interleukin-2 and 5 and 2 g/ml proinsulin peptide, respectively.
MHC class I tetramers and ﬂow cytometry. HLA-A2 tetramers were
produced as previously described (31). Tetramers were titered individually by
staining a relevant peptide-speciﬁc CD8
 T-cell line and used at 5–10 g/ml.
For staining, 10
6 PBMCs were incubated at 37°C for 30 min with 5–10 g/ml
PE-labeled tetramer and then with anti–CD8-APC and anti–CD3-FITC–labeled
antibodies (BD/Pharmingen, San Jose, CA) for 15 min at 4°C. Small lympho-
cytes were gated according to forward/side scatter proﬁles. CD8
 cells were
selected among CD3
 cells. Staining with 7-AAD (Pharmingen) was used to
exclude dead cells. Data were collected on a FACSCalibur ﬂow cytometer and
analyzed using Cell Quest software (Becton Dickinson).
Statistics. Comparison of stimulation score values of patients and control
subjects used nonparametric Mann-Whitney test. Student’s t test was used for
6–14 peptide/HLA-A2 tetramer assessment.
RESULTS
Immunogenicity of HLA-A2–binding peptides. Six pre-
proinsulin peptides (peptides 1–8, 2–11, 6–14, 6–16, 14–
23, and 15–24) selected for predicted binding to HLA-A2
were tested for immunogenicity in HLA-A2 transgenic
mice. As shown in Fig. 1, spleen cells from mice immu-
nized against ﬁve of six preproinsulin peptides (2–11,
6–14, 6–16, 14–23, and 15–24) showed signiﬁcant cyto-
toxic response to HHD-transfected RMA-S cells pulsed
with the immunizing peptide. Immunogenic peptides in-
TABLE 2
Binding of preproinsulin peptides to selected HLA class I alleles
Peptide* Sequence HLA I HLA motif†
Anchoring
ﬁt‡
Binding§ Type of
binder¶ 10
4 10
6
1–8 MALWMRLL A2 MALWMRLL  46 0 L
2–11 ALWMRLLPLL A2 ALWMRLLPLL  55 53 H
A24 ALWMRLLPLL  80 100 H
B8 ALWMRLLPLL  24 20 I
6–14 RLLPLLALL A2 RLLPLLALL  36 65 H
6–16 RLLPLLALLAL A2 RLLPLLALLAL  96 71 H
14–23 LALWGPDPAA A2 LALWGPDPAA  44 36 I
15–24 ALWGPDPAAA A2 ALWGPDPAAA  96 94 H
15–25 ALWGPDPAAAF A1 ALWGPDPAAAF  18 41 I
A24 ALWGPDPAAAF  82 100 H
Data are percent. *NH2- and COOH-terminal positions in preproinsulin. †Anchoring positions are in bold characters. ‡HLA anchoring motifs:
, strict; , tolerated. §Binding (%)  binding of tested peptide/binding of viral reference peptide. ¶L, low binder (binding 	20% at 10
6
mol/l and binding 
20% at 10
4 mol/l); I, intermediate binder (binding between 20 and 50% at 10
6 mol/l); H, high binder (binding 
50% at
10
6 mol/l).
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FIG. 1. Cytotoxic responses of peptide-speciﬁc HLA-A2.1–restricted murine T-cells against preproinsulin peptides. Five to six HHD mice were
immunized in vivo for each preproinsulin peptide (peptides 6–14, [A]; 6–16, [B]; 2–11, [C]; 14–23, [D]; 15–24, [E]; and 1–8, [F]). Spleen cells were
restimulated in vitro 11 days later using irradiated peptide-pulsed HHD lymphoblasts. Spleen cells were then tested for cytolytic activity against
HHD-transfected RMA-S targets loaded with relevant preproinsulin peptide (E) or irrelevant negative control peptide (f) using chromium
release assay. The ﬁgure represents the percentage of speciﬁc lysis (vertical axis) obtained for 1:1, 2:1, 3:1, and 4:1 effector:target (E/T) ratio
(horizontal axis).
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396 DIABETES, VOL. 58, FEBRUARY 2009duced cytotoxic T-cells, which displayed increasing lytic
activity after each of four in vitro restimulations with 1,
0.33, 0.1, and 0.05 g/ml peptide, respectively (data not
shown).
Murine preproinsulin leader sequence-speciﬁc T-cell
clones. As four peptides covered overlapping residues,
murine T-cell clones were generated against preproinsulin
peptides 6–14, 6–16, 14–23, and 15–24. All 6–14– and
6–16–speciﬁc clones were cytotoxic against 6–14– and
6–16–pulsed HHD-transfected RMA-S cells, indicating that
cytotoxic T-cells recognize a unique epitope. As a rule,
clones generated against peptides 6–14 or 6–16 showed
higher cytotoxicity to 6–14–pulsed than to 6–16–pulsed
HHD-transfected RMA-S cells. In contrast, 14–23 and
15–24 peptide-speciﬁc T-cells showed low cross-reactivity
with peptides 15–24 and 14–23, respectively (not shown).
To evaluate processing of peptides 2–11, 6–14, 14–23,
and 15–24 from the source protein, we tested whether
peptide-speciﬁc CD8
 T-cell clones were cytotoxic against
P815 cells cotransfected with the HHD-encoding and hu-
man proinsulin genes (Fig. 2). T-cell clones speciﬁc for
all four preproinsulin peptides were cytotoxic, indicat-
ing that corresponding epitopes were generated from
full-length preproinsulin through the endogenous pro-
cessing pathway.
Binding of selected peptides to HLA-A1, -A2, -A24,
and -B8. Among the six peptides selected for possible
binding to HLA-A2, one peptide (2–11) contained binding
motifs for HLA-A24 and -B8 in addition to HLA-A2. An-
other peptide (15–25) contained binding motifs for HLA-A1
and -A24. These peptides were studied for binding to
puriﬁed HLA molecules. Peptides that yielded 
50, 20–50,
and 	20% binding at 10
6 mol/l were considered high,
intermediate, and low binders, respectively. Four of six
peptides were high binders to HLA-A2 (2–11, 6–14, 6–16,
and 15–24), whereas peptide 14–23 showed intermediate
binding, and peptide 1–8 showed no binding at 10
6 mol/l
and low binding at 10
4 mol/l. Peptide 2–11 was a high
binder to HLA-A24 and an intermediate binder to HLA-B8.
Peptide 15–25 was an intermediate binder to HLA-A1 and
a high binder to HLA-A24. Overall, six peptides showed
binding to HLA class I alleles. Two peptides (2–11 and
15–25) showed high or intermediate binding to different
HLA class I molecules (Table 2). Noticeably, binding of
preproinsulin peptides to class I molecules was weaker
than that of the control viral peptides with the exception
of peptides 2–11 and 15–25, which showed a binding equal
to the reference viral peptide (100% binding) to HLA-A24 at
10
6 mol/l (not shown). Peptide 14–23, which elicited low
cytotoxicity against 14–23–pulsed HHD-transfected
RMA-S cells but signiﬁcant binding to HLA-A2, was in-
cluded in further experiments. Peptide 1–8, showing no
speciﬁc cytotoxicity and no signiﬁcant binding, was ex-
cluded.
Processing of preproinsulin 1–28 by proteasome. We
determined whether COOH-terminal residues of prese-
lected peptides were generated by proteasome digestion.
Database (http://www.paproc2.de.paproc2/cgi-bin) pre-
dicts proteasome cleavage in preproinsulin leader se-
quence in positions 10–14, 16, and 22–24, pointing to
peptides 2–11, 6–14, 6–16, 14–23, and 15–24 as possible
candidates. We analyzed peptides resulting from digestion
of preproinsulin peptide 1–28 by a proteasome-enriched
T1 cell extract (23). Several digestions were performed
that yielded identical HPLC proﬁles. A 20-h incubation was
retained for fraction collection. Multiple peaks appeared
between 18 and 74 min of HPLC column retention time,
and a late peak corresponding to the entire preproinsulin
1–28 peptide was evidenced. Mass spectrometry analysis
of total proteasome digests deﬁned cleavage sites that
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FIG. 2. Cytotoxicity of anti–2–11, anti–6–14, anti–14–23, and anti–15–24 CD8
 T-cell clones against P815 cells transfected with the HHD-encoding
and the human preproinsulin genes. Individual CD8
 T-cell clones were tested for cytolytic activity against HHD- and preproinsulin-transfected
P815 targets loaded with relevant preproinsulin peptide (circles for 2–11, rectangles for 6–14, triangles for 14–23, squares for 15–24; open
symbols) or without peptide (closed symbols, respectively), using chromium release assay. The ﬁgure represents the percentage of speciﬁc lysis
(vertical axis) obtained for 1:1, 2:1, and 3:1 effector:target (E/T) ratio (horizontal axis).
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DIABETES, VOL. 58, FEBRUARY 2009 397clustered in positions 17 and 22–25. HPLC fractions
yielded the same cleavage sites as total digests and addi-
tional cleavage sites in 9–16, 18–21, 26, and 27. Although
numerous cleavage sites predicted by current databases
were conﬁrmed in positions 10–24, cleavage sites that
were not predicted were characterized (in positions 9, 15,
18–21, 26, and 27). The COOH-terminal residues of the six
preselected peptides that showed a signiﬁcant binding to
HLA class I alleles (peptides 2–11, 6–14, 6–16, 14–23,
15–24, and 15–25) were thus generated by proteasome.
Recognition of leader sequence preproinsulin pep-
tides by human T-cells. In our study, the most frequent
class I alleles were HLA-A2 (21 patients and 12 control
subjects), HLA-B8 (17 patients and 8 control subjects),
HLA-A24 (14 patients and 1 control), and HLA-A1 (11
patients and 7 control subjects) (Table 1). Peptide-binding
studies and, in the case of HLA-A2–restricted peptides,
immunogenicity in HHD transgenic mice deﬁned six pos-
sible HLA-A1–, -A2–, -A24–, or -B8–restricted epitopes that
carry COOH-terminal residues generated by proteasome
cleavage in vitro. Preproinsulin and control viral peptides
were tested for recognition by T-cells from control and
type 1 diabetic individuals using an IFN- ELISpot assay.
Viral peptides. To evaluate IFN- responses to known
CD8
 T-cell epitopes, responses of control and patient
PBMCs to viral peptides were studied. Eighteen of 20
HLA-A2 patients and 8 of 11 HLA-A2 control subjects
showed a positive response to inﬂuenza M.58–66 that
ranged between 3 and 20 SD above background. Six of
nine HLA-A1 individuals (3 of 6 patients and 3 of 3 control
subjects) tested against inﬂuenza NP44–52 and 9 of 20
HLA-B8 individuals (7 of 13 patients and 2 of 7 control
subjects) tested against inﬂuenza NP380–388 showed a
positive response that ranged within 3 and 6 SD above
background. No HLA-A2 or -B8 individuals showed a
response to HIV peptides. No difference in the response to
viral peptides used as positive and negative control sub-
jects was observed between diabetic and control individ-
uals (Table 3).
Preproinsulin peptides. All preproinsulin peptides
tested were recognized by PBMCs of diabetic patients
(Tables 4 and 5). When pooling control and patient re-
sponses to preproinsulin peptides, 0 and 65%, respectively,
showed numbers of spots in the presence of peptide that
were 3 SD above background. Setting the threshold for
positive responses at background 3 SD (23), a positive
IFN- response was observed against at least one prepro-
insulin leader sequence peptide with the same frequency
in recent-onset (17 of 26) and long-standing (8 of 12) type
1 diabetic patients. No IFN- response to preproinsulin
peptides was detected in 18 control individuals, including
6 type 2 diabetic patients. Some peptides were recognized
with a comparable frequency in recent-onset and long-
standing diabetic patients, i.e., peptides 6–14 and 6–16 for
HLA-A2. Others peptides were selectively recognized in
recent-onset patients (2–11, 14–23, and 15–24 for HLA-A2;
and 2–11 and 15–25 for HLA-A24). When considering
peptides tested with PBMCs of more than six patients
carrying a deﬁned class I allele, four peptides (2–11 for
HLA-B8, 14–23 and 15–24 for HLA-A2, and 15–25 for
TABLE 3
Recognition of viral peptides by PBMCs of patients and of control individuals
V* Epitope Sequence HLA†
Frequencies of
recognition‡ Responses§
Patients
Control
subjects Patients
Control
subjects
Comparison
(P)
IV M0. 58–66 GILGFVFTL A2 18/20 8/11 89 (0–676) 49 (0–246) 0.36
IV NP 44–52 CTELKLSDY A1 3/6 3/3 39 (7–40) 14 (10–20) 0.43
IV NP 380–388 ELRSRYWAI B8 7/13 2/7 8 (0–119) 5 (2–131) 0.30
HIV Nef 83–91 AAVDLSHFL A2 0/12 0/4 3 (0–20) 0 (0–5) 0.06
HIV Nef 182–189 EWRFDSRLA B8 0/8 0/3 1 (0–35) 0 (0–0) 0.07
Data are n or median (mean). *V, virus; IV, inﬂuenza virus. †HLA, presenting HLA molecule. ‡ELISpot responses, number of responders/
number of individuals tested. §Median (range) of stimulation score; stimulation score  mean number of spots in response to peptide  mean
number of spots in absence of peptide; P, P values comparing the median responses in patients versus control subjects; nonparametric
Mann-Whitney test.
TABLE 4
Relative recognition frequencies of preproinsulin peptides in diabetic versus control subjects
P* HLA
Frequencies of recognition† Comparison
L R C D Patients Control subjects P‡
2–11 A2 0/4 5/17 0/7 0/4 5/21 0/11 0.01
A24 0/4 3/10 0/1 — 3/14 0/1 —
B8 4/10 4/7 0/6 0/2 8/17 0/8 0.0008
6–16 A2 2/4 7/16 0/8 0/4 9/20 0/12 0.0004
6–14 A2 1/4 4/14 0/4 0/2 5/18 0/6 0.01
14–23 A2 0/4 9/14 0/4 0/2 9/18 0/6 0.0003
15–24 A2 1/4 7/13 0/4 0/2 8/17 0/6 0.0008
15–25 A1 2/3 1/3 0/1 — 3/6 0/1 —
A24 0/3 10/10 0/1 — 10/13 0/1 —
Data are n. P, peptide; R, recent-onset diabetes; L, long-standing diabetes; C, healthy control subjects; D, type 2 diabetic control subjects.
*NH2- and COOH-terminal amino acids in preproinsulin. †ELISpot responses, number of responders/number of individuals tested. ‡P values
comparing the relative epitope recognition frequencies in patients (L  R) versus control subjects (C  D); nonparametric Mann-Whitney
test.
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50% of recent-onset pa-
tients. Two peptides (6–16 for HLA-A2 and 2–11 for
HLA-A2 and -A24) were recognized in at least 30% of
recent-onset patients (Table 5).
Characterization of 6–14–speciﬁc T-cells as CD8

T-cells. To set up the staining of CD8
 T-cells with 6–14
peptide/HLA-A2 tetramers, cells from patients L4 and R26
were expanded for 14 days with peptide 6–14 and studied
for recognition of preproinsulin 6–14/HLA-A2 and HIV
gag/HLA-A2 control tetramers. Staining with 6–14/HLA-A2
tetramer was at 1.2 and 0.8% CD8
 T-cells from patients L4
and R26, respectively, whereas the staining with HIVgag/
HLA-A2 tetramer was at 0.08 and 0.04%, respectively (Fig.
3A). In subsequent experiments, some patients who
showed a positive ELISpot response to peptide 6–14 were
studied for 6–14 peptide/HLA-A2 tetramer binding. In four
ELISpot-positive patients, 0.13, 0.14, 0.17, and 0.30% 6–14
peptide/HLA-A2–positive cells were detected in the CD8

T-cell fraction, whereas in ELISpot-negative patients, the
average of 6–14 peptide/HLA-A2 tetramer binding was
0.05  0.01% (range 0.04–0.08%, n  7, P 	 0.02), bringing
evidence that 6–14 peptide-reactive T-cells were clustered
in the CD8
 T-cell subset as shown in an illustrative
experiment (Fig. 3B). For comparison, mean HIV gag/
HLA-A2 tetramer detection in the 11 patients was 0.04 
0.05.
DISCUSSION
Deﬁning epitopes derived from -cell autoantigens is
expected to have wide-range implications in development
of T-cell assays and peptide-based immunotherapy in type
1 diabetes. Although numerous HLA class II–restricted
CD4
 T-cell have been deﬁned in human type 1 diabetes
(14) and transgenic mice expressing human class II alleles
(32–34), epitopes presented by class I alleles to CD8

T-cells remain largely unknown. An HLA-A2–restricted
GAD epitope (GAD 114–123) has been deﬁned as the
target of cytotoxic T-cells in two subjects with preclinical
and recent-onset type 1 diabetes (35). An HLA-A2 epitope
derived from islet amyloid polypeptide (IAPP) has been
characterized using an IFN- ELISpot assay (36). More
recently, new -cell HLA class I–restricted epitopes have
been reported. The proinsulin A chain, B chain, C-peptide,
and leader sequence contain epitopes recognized by CD8

T-cells (17,22,23,37–41). Recognition of epitopes encom-
passing residues excised during insulin processing makes
a strong case for proinsulin as an autoantigen in diabetes.
TABLE 5
Recognition of preproinsulin peptides by PBMCs of diabetic patients: median values of stimulation score
P* HLA
Responses† Comparison‡
L R C D Patients Control subjects P value
2–11 A2 3.3 (0–12.2) 10.0 (0–41.8) 0.56 (0–8.3) 0 (0–0) 7.8 (0–41.8) 0 (0–8.3) 0.01
A24 5.2 (2.2–12.2) 0 (0–41.8) — — 2.8 (0–41.8) — —
B8 25 (0–105) 8.2 (0–37.2) 0 (0–1.1) 0 (0–5.6) 15.6 (0–105) 0 (0–5.6) 0.01
6–16 A2 12.2 (10–54.5) 5 (0–111.7) 0 (0–9.5) 0 (0–0) 7.3 (0–111.7) 0 (0–9.5) 0.004
6–14 A2 28.9 (21.1–51.1) 30.6 (7.8–144) 4.7 (3.9–7.2) — 30.6 (7.8–144) 4.7 (3.9–7.2) 0.01
14–23 A2 11.1 (7.8–12.2) 7.7 (54–0) 1.4 (0–5.6) — 8.9 (54–0) 1.4 (0–5.6) 0.04
15–24 A2 12.8 (2.4–32.2) 8.7 (0–52.8) 0 (0–0) — 12.2 (0–52.8) 0 (0–0) 0.002
15–25 A1 13.6 (6.1–25.6) 1.7 (0–14.4) — — 9.2 (0–25.6) — —
A24 11.1 (5.8–25.6) 0 (0–14.4) — — 0 (0–25.6) — —
Data are median (range). P, peptide; R, recent-onset diabetes; L, long-standing diabetes; C, healthy control subjects; D, type 2 diabetic control
subjects. *NH2- and COOH-terminal amino acids in preproinsulin. †ELISpot responses; median (range) of stimulation score; stimulation
score  mean number of spots in response to peptide  mean number of spots in absence of peptide. ‡P values comparing the median
responses in patients versus control subjects; nonparametric Mann-Whitney test.
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FIG. 3. Peptide/HLA-A2 tetramers staining of CD8
 T-cells from dia-
betic patients. A: Staining of expanded CD8
 T-cells from two diabetic
patients. PBMCs from one long-standing (L4) diabetic patient and one
recent-onset (R26) diabetic patient were cultured in presence of
peptides (peptide 6–14 or HIV gag peptide) and then stained by 6–14
peptide/HLA-A2 and HIV gag peptide/HLA-A2 tetramers. Cultures were
harvested for tetramer staining on day 14. HIV gag peptide/HLA-A2
tetramer was used as a negative control. Detection of tetramer-stained
cells was performed by gating out 7-AAD
 dead cells and selecting
CD8
 T-cells. The ﬁgure shows the staining with 6–14 peptide/HLA-A2
tetramer (left) and with HIV gag peptide/HLA-A2 tetramer (right)a t
day 14 of cell expansion. Dot plots show tetramer (vertical axis) versus
CD8
 cells (horizontal axis) staining. The numbers displayed in each
dot plot indicate the percentages of cells stained by tetramers. B:E x
vivo tetramer staining of PBMCs from 6–14 peptide ELISpot-positive
and ELISpot-negative diabetic patients. PBMCs from 6–14 peptide
ELISpot-positive diabetic patients were stained ex vivo with 6–14
peptide/HLA-A2 and HIV gag peptide/HLA-A2 tetramers. The ﬁgure
shows the ex vivo staining with 6–14 peptide/HLA-A2 tetramer (left)
and with HIV gag peptide/HLA-A2 tetramer (right) for one 6–14
peptide ELISpot-positive patient (R9). As a control, a 6–14 peptide
ELISpot-negative patient (R10).
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sequence epitopes.
Leader sequence peptides are commonly presented to
CD8
, especially HLA-A2–restricted, T-cells (42). Using a
systematic approach to deﬁne class I epitopes derived
from the preproinsulin leader sequence, we bring evidence
that PBMCs from diabetic patients secrete IFN- in re-
sponse to several epitopes. Five preproinsulin leader se-
quence peptides were recognized in 80% HLA-A2 patients.
We did not restrict our study to epitopes showing the
highest binding afﬁnity to puriﬁed class I molecules be-
cause rules governing the spectrum of epitopes presented
in autoimmunity remain far from clear. All ﬁve peptides
that showed signiﬁcant binding to puriﬁed HLA-A2 mole-
cules in vitro were highly immunogenic in HHD transgenic
mice. One peptide (proinsulin 2–11) was recognized in 57%
HLA-B8 and 30% HLA-A24 recent-onset diabetic patients.
Two peptides covering the 6–16 preproinsulin region
correspond to the same epitope because 6–14– and 6–16–
speciﬁc T-cell clones recognize indistinctly both peptides.
In contrast, the 14–25 region contains two epitopes that
are distinctly recognized by 14–23– and 15–24–speciﬁc
peptides. Using 6–14/HLA-A2 tetramers, we bring direct
evidence that preproinsulin peptide 6–14 is recognized by
human CD8
 T-cells. In contrast, the small number of
patients studied using tetramers preclude ﬁrm conclusions
as to the concordance observed between IFN- production
and tetramer staining.
In most patients, the response to preproinsulin leader
sequence was multiepitopic. The long preclinical phase
characterizing diabetes development does not preclude,
however, that a more restricted set of peptides is domi-
nantly recognized at initiation of the autoimmune process,
as reported in case of a CD4
 T-cell–restricted epitope in
the NOD mouse (43). A2-restricted GAD, IAPP, and pre-
proinsulin peptide 2–10 were predominantly recognized in
recent-onset diabetic patients (35,36,27). This was the case
in our study for peptides 2–11 and 14–23, although not for
HLA A2–restricted peptide 6–14. It should be acknowl-
edged that our data do not directly correlate recognition of
preproinsulin peptides by CD8
 T-cells and the absence of
residual C-peptide in long-standing diabetic patients stud-
ied. However, a comparable observation was reported for
other proinsulin epitopes (23) and may reconcile with
previous observations in human type 1 diabetes (7). This
may indicate that long-term memory class I–restricted
T-cells persist in patients who are likely to have been
deprived of remnant -cells for years while on exogenous
insulin therapy. Finally, the evidence that murine T-cell
clones that were speciﬁc for leader sequence preproinsu-
lin peptides were cytotoxic to P815 target cells expressing
the human preproinsulin gene indicate that corresponding
CD8
 T-cells may point to useful disease markers.
Using a strategy based on peptide library-mediated in
vitro assembly of class I molecules, preproinsulin peptides
have been deﬁned on the basis of their association with
HLA-B8, -A2, and -B15. Several epitopes were shown to
harbor anchor residues that were weakly predicted by
commonly used algorithms or did not contain canonical
allele-speciﬁc binding motifs (44). In our study, some of
these peptides were recognized in 
40% of patients, such
as preproinsulin 2–11 in HLA-B8; 6–16, 14–23, and 15–24 in
HLA-A2; or 15–25 in both HLA-A1 and -A24 patients.
Proteasome-mediated proteolysis is a major, although
not exclusive, system generating COOH termini of class I
epitopes. Intracellular mechanisms that deﬁne the se-
quence of peptides presented to CD8
 T-cells include, in
addition, peptide translocation in the endoplasmic reticu-
lum by transporter associated with antigen processing
(TAP) and binding of peptides into the MHC class I groove.
As reported in case of viral epitopes (45), we used 20S
proteasome–enriched preparations extracted from the T1
lymphoblastoid cell, which contains IFN-–inducible
LMP-2 and LMP-7 proteasome subunits. Among candidate
peptides, six carried COOH-terminal ﬂanking residues that
were identiﬁed after proteasome processing in vitro. One
peptide (1–8) that carried a leucine in position 8 was not
identiﬁed as a proteasome cleavage site. This is not
unexpected because many peptides from signal sequences
have been characterized as presented by class I alleles in
a proteasome-independent and TAP-independent manner
(46,47). However, this peptide showed no detectable bind-
ing to HLA-A2 nor immunogenicity in HHD transgenic
mice. In contrast, peptide 2–11 showed signiﬁcant binding
to HLA-A2, signiﬁcant immunogenicity in HHD transgenic
mice and recognition by PBMCs from 29% HLA-A2 and 57%
HLA-B8 diabetic patients.
Considering previous reports (23,26) and the present
data, at least nine HLA-A2–restricted epitopes have been
identiﬁed as recognized by CD8
 T-cells from type 1
diabetic patients within preproinsulin. Similar evidence
that points to the high diversity of epitopes recognized by
CD8
 T-cells within restricted regions of myelin autoanti-
gens has been obtained in multiple sclerosis, in contrast
with the limited number of immunodominant epitopes
usually reported on viral antigens (48). Furthermore,
epitope diversity was not restricted to HLA-A2 in multiple
sclerosis (49). In the same line, there was no clear corre-
lation between the prevalence of positive responses to
peptides within the restricted preproinsulin region studied
and afﬁnity levels of peptide binding to HLA class I
molecules. In vivo priming in HHD mice and study of
peptide binding in vitro possibly biased our peptide selec-
tion procedure toward peptides with signiﬁcant afﬁnity,
possibly underestimating the number of peptides recog-
nized along diabetes development. However, frequent re-
sponses to intermediate afﬁnity peptides were observed,
such as proinsulin 2–11 in HLA-B8 and 14–23 in HLA-A2
patients. Because autoimmune reactions develop against
self proteins, the autoantigen-speciﬁc T-cell repertoire is
expected to be purged from high-avidity T-cells speciﬁc for
dominant T-cell epitopes, opening the likelihood of auto-
reactive T-cells that are speciﬁc for subdominant or cryp-
tic epitopes.
Our data bring evidence that type 1 diabetic patients
shows class I–restricted responses to 8- to 11-mer peptides
within the preproinsulin leader sequence. The absence of
recognition of preproinsulin peptides by PBMCs from
control individuals may point to leader sequence prepro-
insulin-speciﬁc CD8
 T-cells as useful disease markers.
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